Active, not recruitingNCT05145062
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
Studying Beta-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sangamo Therapeutics
- Principal Investigator
- Medical MonitorSangamo Therapeutics
- Intervention
- BIVV003(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18-45 years · All sexes
- Timeline
- 2021 – 2038
Study locations (7)
- UCSF Benioff Children's Hospital, Oakland, California, United States
- University of California Davis Health System, Sacramento, California, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Henry Ford Health System, Detroit, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05145062 on ClinicalTrials.govOther trials for Beta-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07215975A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastBristol-Myers Squibb
- ENROLLING BY INVITATIONNCT07055503Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia PatientsUniversity Research Institute for the Study of Genetic & Malignant Disorders in Childhood
- RECRUITINGNANCT07207577Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTDCentre Hospitalier Metropole Savoie
- ENROLLING BY INVITATIONNCT06717932A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionCorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT06364774ALS20-101 Lentiviral Gene Therapy for Beta ThalassemiaChildren's Hospital of Philadelphia
- ENROLLING BY INVITATIONNCT06685536A Long-term Follow-up Study in Participants Who Received CS-101CorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1NCT06772766A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaMabwell (Shanghai) Bioscience Co., Ltd.
- RECRUITINGNANCT06734520Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemiaGuangzhou Women and Children's Medical Center